Benzinga | Apr 28, 2021 04:34PM EDT

Aziyo Biologics Announces Initiation of De Novo CanGaroo Clinical Study

Aziyo Biologics, Inc. (NASDAQ:AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today the initiation of a multi-center observational study to provide insight into the clinical profiles, procedural details and post-implant outcomes in patients receiving Aziyo's CanGaroo(r) Envelope or no envelope during initial (de novo) cardiac implantable electronic device (CIED) placement.

The prospective, multi-center study anticipates enrolling up to 500 participants who are undergoing implementation of a CIED with either a CanGaroo Envelope (approximately 330 patients) or no envelope (approximately 170 participants).